Market Newsdesk

DALLAS
, July 8, 2025 /PRNewswire/ — Braemar Hotels & Resorts Inc. (NYSE: BHR) (“Braemar” or the “Company”) today announced that it has entered into a definitive agreement to sell the 369-room Marriott Seattle Waterfront in Seattle for $145 million ($393,000 per key). Including anticipated capital expenditures of $7 million, the sale price represents an 8.1% capitalization rate on net operating income for the trailing 12 months ended May 31, 2025. 

“We are pleased to announce the planned sale of the Marriott Seattle Waterfront,” said Richard J. Stockton, Braemar’s president and CEO. “The sale of this upper upscale hotel will help deleverage our portfolio and further align our financial performance with the luxury hotel sector.”

The transaction is expected to close in August 2025, subject to customary conditions. The Company provides no assurances that the sale will be completed on these terms or at all. 

*  *  *  *  *

Braemar Hotels & Resorts is a real estate investment trust (REIT) focused on investing in luxury hotels and resorts.

_________

All information in this table is based upon unaudited operating financial data for the twelve month period ended May 31, 2025. This data has not been audited or reviewed by the Company’s independent registered public accounting firm. The financial information presented could change.

EBITDA is defined as net income (loss), computed in accordance with generally accepted accounting principles (“GAAP”), before interest, taxes, depreciation and amortization. Hotel EBITDA multiple is defined as the purchase price divided by the trailing 12 month EBITDA. A capitalization rate is determined by dividing the property’s annual net operating income by the purchase price. Net operating income is the property’s hotel EBITDA minus a capital expense reserve of 5% of gross revenue.

Forward-Looking Statements

Certain statements and assumptions in this press release contain or are based upon “forward-looking” information and are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, among others, statements about the Company’s strategy and future plans. These forward-looking statements are subject to risks and uncertainties. When we use the words “will likely result,” “may,” “anticipate,” “estimate,” “should,” “expect,” “believe,” “intend,” or similar expressions, we intend to identify forward-looking statements. Such statements are subject to numerous assumptions and uncertainties, many of which are outside Braemar’s control.

These forward-looking statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those anticipated, including, without limitation: our ability to repay, refinance or restructure our debt and the debt of certain of our subsidiaries; anticipated or expected purchases or sales of assets; our projected operating results; completion of any pending transactions; risks associated with our ability to effectuate our dividend policy, including factors such as operating results and the economic outlook influencing our board’s decision whether to pay further dividends at levels previously disclosed or to use available cash to pay dividends; our understanding of our competition; market trends; projected capital expenditures; the impact of technology on our operations and business; general volatility of the capital markets and the market price of our common stock and preferred stock; availability, terms and deployment of capital; availability of qualified personnel; changes in our industry and the markets in which we operate, interest rates or the general economy; and the degree and nature of our competition. These and other risk factors are more fully discussed in Braemar’s filings with the Securities and Exchange Commission.

The forward-looking statements included in this press release are only made as of the date of this press release. Such forward-looking statements are based on our beliefs, assumptions, and expectations of our future performance taking into account all information currently known to us. These beliefs, assumptions, and expectations can change as a result of many potential events or factors, not all of which are known to us. If a change occurs, our business, financial condition, liquidity, results of operations, plans, and other objectives may vary materially from those expressed in our forward-looking statements. You should carefully consider this risk when you make an investment decision concerning our securities. Investors should not place undue reliance on these forward-looking statements. The Company can give no assurance that these forward-looking statements will be attained or that any deviation will not occur. We are not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or circumstances, changes in expectations, or otherwise, except to the extent required by law.

View original content:https://www.prnewswire.com/news-releases/braemar-hotels–resorts-announces-agreement-to-sell-marriott-seattle-waterfront-302500056.html

SOURCE Braemar Hotels & Resorts, Inc.

SAN JOSE, Calif.
, July 8, 2025 /PRNewswire/ — Harmonic (NASDAQ: HLIT) today announced a record-breaking demonstration at the recent CableLabs^® Interop event, setting a new industry benchmark for DOCSIS^® 4.0 performance. Harmonic’s market-leading cOS™ virtualized broadband platform delivered an impressive 14 Gbps of downstream throughput across a multi-vendor network. This milestone achievement underscores Harmonic’s continued broadband innovation and leadership, empowering operators to meet multigigabit connectivity demands with outstanding reliability.

“Interoperability testing at CableLabs plays a critical role in accelerating the deployment of DOCSIS technologies by enabling vendors to validate functionality in a collaborative, multi-vendor environment,” said Doug Jones, principal architect at CableLabs. “These intensive sessions — which involve numerous upgrade cycles — are instrumental to advancing modem, RPD and Core interoperability and ensuring readiness for certification. The recent achievement of 14 Gbps downstream DOCSIS throughput across a multi-vendor cable network is a testament to their impact. Continued participation from companies like Harmonic, who have been consistently engaged throughout our DOCSIS 4.0 interop events, supports the broader industry’s ability to deliver reliable, high-speed broadband solutions.”

The interoperability event featured Harmonic’s cOS broadband platform and Pebble-2 DOCSIS 4.0 Remote PHY Device (RPD) delivering 14 Gbps downstream, far surpassing the 10 Gbps DOCSIS 4.0 benchmark target. Harmonic’s cOS platform is the industry’s first solution to unify both modes of DOCSIS 4.0 technology — Full Duplex (FDX) and Frequency Division Duplex (FDD), giving operators the flexibility to choose the deployment strategy that best matches their business and network needs.

“This major milestone demonstrates that our cOS platform is primed to support DOCSIS 4.0 rollouts, enabling the standard’s full set of downstream and upstream speed options with fiber-like symmetric multigigabit speeds,” said Asaf Matatyaou, senior vice president, product, at Harmonic. “Harmonic continues to push the boundaries of what’s possible through innovation and collaboration to lead the broadband industry’s transformation and shape the future of connectivity.”

Harmonic is the market share leader in cable broadband equipment, virtual CMTS and DAA, according to Dell’Oro Group, the trusted source for market information about the telecommunications, networks and data center IT industries. The company’s market-leading cOS platform powers next-gen broadband services through more than 33 million customer premises equipment (CPE) devices worldwide for leading operators in North America, Europe, Latin America and Asia. 

To learn more about Harmonic’s broadband solutions, visit www.harmonicinc.com/broadband.

About Harmonic
Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry’s first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet services to consumers’ homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at www.harmonicinc.com. 

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning Harmonic’s business and the anticipated capabilities, advantages, reliability, efficiency, market acceptance, market growth, specifications and benefits of Harmonic products, services and technology are forward-looking statements. These statements are based on our current expectations and beliefs and are subject to risks and uncertainties, including the risks and uncertainties more fully described in Harmonic’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2024, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. The forward-looking statements in this press release are based on information available to Harmonic as of the date hereof, and Harmonic disclaims any obligation to update any forward-looking statements.

Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmonic-sets-docsis-4-0-record-with-14-gbps-downstream-speed-at-cablelabs-interoperability-event-302499744.html

SOURCE Harmonic Inc.

MILWAUKEE
, July 8, 2025 /PRNewswire/ — Regal Rexnord Corporation (NYSE: RRX) announced today that it plans to release its second quarter 2025 financial results after the market closes on Tuesday, August 5, 2025.

Regal Rexnord will host a conference call to discuss the earnings release at 9:00 am CT (10:00 am ET) on Wednesday, August 6, 2025. To listen to the live audio and view the presentation during the call, please visit Regal Rexnord’s Investor website: https://investors.regalrexnord.com. To listen by phone or to ask the presenters a question, dial 1-877-264-6786 (U.S. callers) or +1-412-317-5177 (international callers) and enter 3362702# when prompted.

A webcast replay will be available at the link above, and a telephone replay will be available at 1-877-344-7529 (U.S. callers) or +1-412-317-0088 (international callers), using a replay access code of 4250765#. Both will be accessible for three months after the earnings conference call.

About Regal Rexnord

Regal Rexnord’s 30,000 associates around the world help create a better tomorrow by providing sustainable solutions that power, transmit and control motion. The Company’s electric motors and air moving subsystems provide the power to create motion. A portfolio of highly engineered power transmission components and subsystems efficiently transmits motion to power industrial applications. The Company’s automation offering, comprised of controllers, drives, precision motors, and actuators, controls motion in applications ranging from factory automation to precision tools used in surgical applications.

The Company’s end markets benefit from meaningful secular demand tailwinds, and include discrete automation, food & beverage, aerospace, medical, data center, energy, residential and commercial buildings, general industrial, and metals and mining.

Regal Rexnord is comprised of three operating segments: Industrial Powertrain Solutions, Power Efficiency Solutions, and Automation & Motion Control. Regal Rexnord is headquartered in Milwaukee, Wisconsin and has manufacturing, sales and service facilities worldwide. For more information, including a copy of our Sustainability Report, visit RegalRexnord.com.

 

View original content:https://www.prnewswire.com/news-releases/regal-rexnord-corporation-to-host-second-quarter-2025-earnings-conference-call-on-wednesday-august-6-2025-302499483.html

SOURCE Regal Rexnord Corporation

HENDERSON, Nev.
, July 8, 2025 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces it has demonstrated quantification of nucleosomes in whole venous blood in minutes utilizing a simple lateral flow device. The blinded study, part of the SUMMIT program,  tested blood samples from 25 hospital patients in Intensive Care or at the Emergency Department. The results correlated strongly with those of Volition’s established automated central laboratory Nu.Q® nucleosome assay, demonstrating the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly in a doctor’s office, Emergency Department or Intensive Care setting without the need to send a blood sample to a hospital laboratory for testing.

Mr. Gael Forterre, Chief Commercial Officer, Volition said:

“The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes.

“This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in providing our tests to lower-income countries where laboratory infrastructure may be weak or non-existent.

“This technological breakthrough is the first report of a bedside lateral flow test to quantify nucleosomes, a marker of NETosis. It is not simply a positive/ negative test but provides a quantitative readout to facilitate clinical decision-making.

“The next phase of the SUMMIT program is to demonstrate use with capillary blood, with the ultimate goal of providing a finger-prick test for additional use cases.”

About SUMMIT (Sepsis: addressing unmet needs for disease monitoring with a rapid test)

This innovative project, aimed at developing a capillary blood-based Lateral Flow test for the early diagnosis of sepsis, is carried out with the financial support of the Walloon Region.

About Lateral Flow Tests

The first commercial Lateral Flow Test (LFT), the Clearblue pregnancy test, was launched in the late 1980s. More recently, LFTs for COVID-19 virus were widely used during the COVID-19 pandemic. LFTs are designed to rapidly detect a molecule of interest in a simple test that can be conducted immediately on a patient’s blood, urine or saliva sample in a doctor’s office or even a home setting by a person with no scientific training and using no specialized equipment.

About Volition’s Nu.Q® Nucleosome Assay

The Volition Nu.Q® nucleosome assay is a chemiluminescent immunoassay (ChLIA) that runs on the  Immunodiagnostic Systems (IDS) i10® automated analyzer platform. It holds a CE Mark to aid in the detection and evaluation of diseases associated with NETosis and is available in 27 European Countries.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  

The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, [email protected] +44 (0)7557 774620

Investor Relations:

Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition’s expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition’s cost reduction measures, the effectiveness and availability of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition’s success in securing licensing and/or distribution agreements with third parties for its products. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-announces-groundbreaking-lateral-flow-test-for-point-of-care-quantification-of–nucleosomes-302499966.html

SOURCE VolitionRx Limited

RICHMOND, Va.
, July 8, 2025 /PRNewswire/ — Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior.

“We are excited to welcome Vanessa to the Indivior team,” said Joe Ciaffoni, Chief Executive Officer. “Vanessa has an impressive track record of aligning teams to priorities and executing successful multi-stakeholder strategies that drive patient access in complex regulatory environments. We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder.”

“I am honored to join Indivior at this transformative time for the Company,” said Ms. Procter. “Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding and systems necessary to ensure treatment in the right place and at the right time. I look forward to working with the Indivior team and deepening our engagement with the people and communities we serve to further this important work.”

Ms. Procter brings 25 years of experience in the biopharmaceutical industry, having led corporate and government affairs for multiple organizations. Most recently, Ms. Procter was Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led a team that conditioned the environment for the successful product launch of ZURZUVAE™, the first pill for post-partum depression. In that role, she led corporate communications, investor relations, government affairs and patient advocacy. Prior to her time at Sage, she was Head of U.S. Government Affairs and Public Policy at Alexion Pharmaceuticals, helping expand patient access to existing and new medical therapies. Earlier, Ms. Procter worked at MedImmune as Director of Federal Government Affairs. Before that, she was a health policy advisor in the U.S. House of Representatives.

Ms. Procter earned her B.A. in History from Gettysburg College.

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-appoints-vanessa-procter-as-executive-vice-president-of-corporate-affairs-302499820.html

SOURCE Indivior PLC

FAIRFAX, Va.
, July 8, 2025 /PRNewswire/ — CGI (TSX: GIB.A) (NYSE: GIB), one of the largest independent technology and professional services firms, today announced the successful launch of an upgraded financial and administrative system for the City of Rockville, Maryland. The transformation moves Rockville’s existing systems to the upgraded CGI Advantage^® enterprise resource planning (ERP) platform, a cloud-based solution providing the City with enhanced capabilities, streamlined processes, and improved operational efficiency.

The transition – part of an ongoing partnership between the City and CGI – encompasses critical functions including finance, procurement, inventory, human resources, and reporting. Additional enhancements, such as vendor self-service and open enrollment, are planned to follow in subsequent phases.

“Our partnership with CGI is built on trust and a shared commitment to operational excellence,” said Rockville Chief Information Officer Nicholas Obodo. “This upgrade ensures we can continue meeting the evolving needs of our employees and residents.”

Rockville’s upgraded solution introduces a faster, more intuitive interface designed to improve the experience for remote and in-office employees alike. Enhanced tools promote productivity while enabling seamless access to essential information. Additionally, CGI Advantage lays the groundwork for increased transparency and visibility into government operations, ensuring greater confidence and stronger engagement with the community.

The City of Rockville has trusted CGI to manage its financial systems for over 30 years. This milestone marks a pivotal step in the City’s modernization journey, bolstered by CGI’s proven track record of delivering secure, integrated, and scalable solutions tailored to the unique challenges and requirements of the public sector.

“Our longstanding partnership with the City of Rockville demonstrates the value of collaboration in achieving transformative outcomes and reflects a shared commitment to modernization and public service. CGI Advantage empowers the City’s IT professionals to focus on oversight and innovation rather than system maintenance. Automatic updates and enhancements ensure that Rockville benefits from the latest features, improved security, and reduced support costs, resulting in a more efficient and user-friendly system,” said Kathleen Galvin, Vice-President, Consulting Services at CGI. “With CGI Advantage, the City is well-positioned to deliver vital services today and well into the future.”

About CGI Advantage
CGI Advantage is a unified ERP platform featuring a powerful combination of modern technology and built-for-government solutions. This secure, intuitive platform organically meets state and local government requirements and streamlines financial management, human resources, performance budgeting, procurement, and business intelligence operations. A proven solution, CGI Advantage is based on more than 46 years of public sector expertise and is supported by an active client community that values innovation and access to CGI’s global network of experts. Learn more at cgi.com/advantage.

About CGI
Founded in 1976, CGI is among the largest independent technology and professional services firms in the world. With 94,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2024 reported revenue is CA$14.68 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.

Stock Market Symbols

GIB (NYSE)

GIB.A (TSX)

www.cgi.com/newsroom

View original content:https://www.prnewswire.com/news-releases/cgi-partners-with-city-of-rockville-to-transform-the-citys-financial-hr-and-procurement-systems-with-cloud-based-cgi-advantage-302499259.html

SOURCE CGI Technologies and Solutions, Inc.

Testing proves maturity as program moves closer to initial operational capability

PORTSMOUTH, R.I.
, July 8, 2025 /PRNewswire/ — Raytheon, an RTX (NYSE: RTX) business, has successfully demonstrated its Barracuda mine neutralization vehicle in an untethered, semi-autonomous operation for the first time during recent open water testing in Narragansett Bay.

During the demonstration, Raytheon’s Barracuda proved its ability to autonomously navigate, communicate, detect and identify targets, and operate independently underwater.

“This recent testing demonstrates the significant strides we’ve made in advancing mine countermeasure technology,” said Barbara Borgonovi, president of Naval Power at Raytheon. “Barracuda’s capabilities will dramatically improve safety and efficiency for the U.S. Navy, keeping sailors out of harm’s way while effectively addressing underwater threats.”

Barracuda is the newest U.S. Navy program of record for mine neutralization. It is the first untethered, semi-autonomous mine neutralization system capable of tracking and identifying bottom, volume and near-surface mines with man-in-the-loop delivering a final decision for neutralization. The program started in research and development within Raytheon’s Advanced Technology business segment – a group of innovators that matures technologies that are incorporated into Raytheon products including franchise programs such as LTAMDS and SPY-6.

In line with the Navy’s acquisition plan, Raytheon’s Barracuda is on track to achieve initial operational capability and low-rate initial production by 2030. In addition to executing mine neutralization missions, the company is investing in developing a larger and more advanced variant to meet different mission sets such as subsea and seabed warfare.

About Raytheon
Raytheon, an RTX business, is a leading provider of defense solutions to help the U.S. government, our allies and partners defend their national sovereignty and ensure their security. For more than 100 years, Raytheon has developed new technologies and enhanced existing capabilities in integrated air and missile defense, smart weapons, missiles, advanced sensors and radars, interceptors, space-based systems, hypersonics and missile defense across land, air, sea and space.

About RTX
RTX is the world’s largest aerospace and defense company. With more than 185,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. Through industry-leading businesses – Collins Aerospace, Pratt & Whitney and Raytheon – we are advancing aviation, engineering integrated defense systems for operational success, and developing next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2024 sales of more than $80 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact

[email protected]

.

 

View original content:https://www.prnewswire.com/news-releases/rtxs-raytheon-demonstrates-autonomous-capabilities-of-its-barracuda-mine-neutralizer-302499655.html

SOURCE RTX

Customers can now use Oracle Database@AWS in AWS Regions in Northern Virginia and Oregon, with planned expansion to 20 more 

Enterprises including Fidelity Investments, Nationwide, and SAS are adopting Oracle Database@AWS to migrate and run Oracle Exadata Database Service and Oracle Autonomous Database on OCI within AWS 

AUSTIN, Texas and SEATTLE, July 8, 2025 /PRNewswire/ — Oracle and Amazon Web Services, Inc. (AWS) today announced the general availability of Oracle Database@AWS. Customers can now run Oracle Exadata Database Service and Oracle Autonomous Database on dedicated infrastructure on Oracle Cloud Infrastructure (OCI) within AWS. Oracle Database@AWS is available in the AWS U.S. East (N. Virginia) and U.S. West (Oregon) Regions, with plans to expand availability to 20 additional AWS Regions around the world.

Customers can easily migrate their Oracle Database workloads to Oracle Database@AWS running on OCI in AWS while taking advantage of Oracle Real Application Clusters (RAC) and the latest Oracle Database 23ai with embedded AI Vector capabilities. Oracle Database@AWS includes zero-ETL (extract, transform, and load) integration, which simplifies data integration between enterprise Oracle Database services and AWS Analytics services, eliminating the need to build and manage complex data pipelines. This allows data to flow seamlessly between Oracle Database services and AWS services, giving customers the ability to combine their data with AWS analytics, machine learning, and generative AI services to further enhance their applications. These capabilities expand customers’ choices for running their databases in the cloud and complements existing options to run Oracle Database workloads within AWS. 

“Enterprise customers can seamlessly migrate their Oracle database workloads to Oracle Database@AWS without rearchitecting applications, all while benefitting from the security, resiliency, and scalability of AWS’s global infrastructure,” said G2 Krishnamoorthy, vice president, Database Services, AWS. “Many of the world’s largest and most security-sensitive organizations already trust AWS with their Oracle workloads, and Oracle Database@AWS makes it even easier for enterprises to unlock greater value from their data with AWS’s advanced analytics and generative AI capabilities.”

“Customers have been putting their most valuable data in Oracle databases for decades,” said Karan Batta, senior vice president, Oracle Cloud Infrastructure. “Oracle Database@AWS lets them run Oracle Database workloads on OCI in AWS. This allows customers to take full advantage of Oracle Database 23ai to simplify application development and run mission-critical workloads with AI and native vector embeddings. Combined with AWS’s advanced generative AI and analytics services, this gives customers a truly remarkable solution.”

Oracle Database@AWS Simplifies IT Modernization and Innovation

Oracle Database@AWS provides customers with a unified experience across OCI and AWS, featuring fully integrated support from both companies that simplifies database administration, purchasing, and deployment through reference architectures and landing zones designed for customers’ most trusted enterprise applications. Customers can also benefit from:

• Simplifying and accelerating the migration of their Oracle databases to the cloud, including compatibility with proven migration tools such as Oracle Zero Downtime Migration.
• Highly resilient and scalable workloads with Oracle RAC, multiple AWS Availability Zones, and Amazon S3 for database backups and disaster recovery.
• A simplified procurement experience via AWS Marketplace. Customers can use their existing AWS commitments and Oracle license benefits, including Bring Your Own License (BYOL) and discount programs such as Oracle Support Rewards (OSR) with Oracle Database@AWS.
• Building new, scalable microservices-based applications by combining Amazon EC2, Amazon EKS, and Amazon ECS with Oracle Database features like AI Vector Search to enhance application intelligence and accelerate time to market for new features.
• Oracle Database@AWS offers Oracle Database 23ai that supports embedded Oracle AI Vector Search, providing customers with a simple way to search documents, images, and relational data based on their conceptual content rather than specific words, pixels, or data values.
• Familiar tools such as AWS Management Console, AWS Command Line Interface, APIs, and monitoring to easily manage their workloads while preparing their data for use with advanced analytics, machine learning, and generative AI services, as well as integrations with AWS services including AWS Identity and Access Management (IAM), AWS CloudFormation, Amazon CloudWatch, Amazon VPC Lattice, and Amazon EventBridge.
• Support for Oracle applications such as Oracle E-Business Suite, PeopleSoft, JD Edwards EnterpriseOne, Oracle Enterprise Performance Management, and Oracle Retail Applications.

Leading Organizations Choose Oracle Database@AWS
Early adopters across almost all sectors of business, including highly regulated industries such as telecommunications, energy, and financial services are leveraging Oracle Database@AWS to solve complex business challenges, reporting improvements in operational efficiency and delivering value to their customers.

“Fidelity Investments continues to advance our digital transformation and maintain the enterprise-grade resilience that is essential for managing the critical applications that our customers depend on every day,” said Joe Frazier, head of Fidelity architecture and engineering, Fidelity Investments. “When you address the need for both cloud agility and performance, you are able to innovate faster, scale more efficiently, and deliver the secure, responsive experiences that strengthen the financial well-being of millions of customers.” 

“At Nationwide, we’re focused on delivering secure, scalable, and innovative protection solutions for our members,” said Jim Fowler, chief technology officer, Nationwide. “Oracle Database@AWS aligns with our cloud strategy, enabling us to streamline operations and accelerate innovation while maintaining the reliability and performance our customers expect. It’s an important part of our long-term technology roadmap.”

“At SAS, we make it a priority to empower our customers to operate in the cloud of their choice with the experiences—and outcomes—that suit their business goals and help them meet their AI aspirations,” said Jay Upchurch, chief information officer, SAS. “Oracle Database@AWS’s integrated capabilities gives them high-performance access to their applications and data in AWS.”

Oracle Database@AWS Continues Expansion Across Global Regions
Oracle Database@AWS is now available in the AWS U.S. East (N. Virginia) and U.S. West (Oregon) Regions, leveraging AWS’s extensive cloud infrastructure. In addition, the Oracle Database@AWS offering is planned to be available in 20 more AWS Regions, including: Canada (Central), Frankfurt, Hyderabad, Ireland, London, Melbourne, Milan, Mumbai, Osaka, Paris, São Paulo, Seoul, Singapore, Spain, Stockholm, Sydney, Tokyo, U.S. East (Ohio), U.S. West (N. California) and Zurich.

Additional Resources

• Read more about the general availability of Oracle Database@AWS 
• Learn more about how to use Oracle Database@AWS for simplified Oracle Exadata migrations
• Learn more about Oracle Database@AWS on AWS Marketplace
• View purchase options for Oracle Database@AWS
• Learn more about OCI’s distributed cloud
• Learn more about Oracle database services, Oracle Autonomous Database, Oracle Exadata Database Service, and Oracle Base Database Service

About Oracle Distributed Cloud
Oracle’s distributed cloud delivers the benefits of cloud with greater control and flexibility. Oracle’s distributed cloud lineup includes:

• Public cloud: Hyperscale public cloud regions serve any size of organization, including those requiring strict EU sovereignty controls. See the full list of regions here.
• Dedicated cloud: Customers can run all OCI cloud services in their own data centers with OCI Dedicated Region, while partners can resell OCI cloud services and customize the experience using Oracle Alloy. Oracle also operates separate U.S., UK, and Australian Government Clouds, and Isolated Cloud Regions for national security purposes. Each of these products provide a full cloud and AI stack that customers can deploy as a Sovereign Cloud.
• Hybrid cloud: OCI delivers key cloud services on-premises via Oracle Exadata Cloud@Customer and Compute Cloud@Customer and is already managing deployments in over 60 countries. Additionally, OCI Roving Edge Infrastructure, which consists of multiple configurations of ruggedized and portable high-performance devices, helps customers leverage remote AI inferencing at the edge. 
• Multicloud: OCI is physically deployed within all the hyperscale cloud providers, including AWS, Google Cloud, and Microsoft Azure, providing low latency, natively integrated Oracle Database services, including Oracle Database@AWS, Oracle Database@Azure, Oracle Database@Google Cloud and Oracle HeatWave on AWS and Microsoft Azure.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

About Amazon Web Services
Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 117 Availability Zones within 37 geographic regions, with announced plans for 13 more Availability Zones and four more AWS Regions in Chile, New Zealand, the Kingdom of Saudi Arabia, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

Future Product Disclaimer
The above is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, timing, and pricing of any features or functionality described for Oracle’s products may change and remains at the sole discretion of Oracle Corporation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/oracle-databaseaws-now-generally-available-302499578.html

SOURCE Oracle

New platform, powered by Pollinate, unifies business banking and merchant services to simplify operations and deliver intelligent insights

CHARLOTTE, N.C., July 8, 2025 /PRNewswire/ — Truist Financial Corporation (NYSE: TFC) today unveiled Truist Merchant Engage, a new integrated merchant services platform designed to help small and medium-sized businesses (SMBs) streamline operations, gain real-time insights and scale with certainty. The launch marks a significant expansion of Truist’s payments product suite and underscores the company’s commitment to delivering modern, scalable technology that deepens client relationships and drives focused growth.

This milestone reinforces Truist’s ongoing investment in innovative payments technology — built to meet evolving client needs and position the bank at the forefront of digital financial services. The rollout, which began in late June and will continue into early 2026, marks a major step in Truist’s journey to modernize business banking and deliver integrated, insight-driven solutions. It also marks the U.S. debut of the Pollinate platform, with Truist as the first U.S. bank to bring this solution to market.

Truist Merchant Engage offers a smarter approach to serving business clients by unifying core financial services and merchant solutions into a single, intuitive digital experience. The platform features real-time dashboards, dynamic onboarding, product discovery and self-service tools that simplify operations and unlock insights.

Many of the over 30 million SMBs in the U.S. — representing 99% of all businesses — still rely on non-integrated payments and business services providers, costing them up to a full day each week in administrative tasks. Valued at approximately $40 billion, the U.S. merchant acquiring market presents a significant opportunity.

“At Truist, our approach to payments is built on simplicity, speed, and safety — principles that guide how we create meaningful value for our clients,” said Truist Head of Enterprise Payments Chris Ward. “Truist Merchant Engage is more than a product — it’s a reflection of our purpose-driven commitment to lead the industry with integrated solutions that help businesses thrive. By unifying business banking and merchant services into one seamless experience, we’re enabling SMBs to operate more efficiently, make data-driven decisions and grow with confidence.”

“Our partnership with Truist is about helping a forward-looking institution deliver on its promise to small and medium-sized business customers,” said Pollinate CEO Fiona Roach Canning. “Banks have the product breadth to serve SMBs better than anyone — but what’s been missing is the experience layer to unify merchant acquiring with business banking. Pollinate helps banks bring this together in a way that’s intuitive, intelligent and built for modern business owners.”

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $536 billion as of March 31, 2025. Truist Bank, Member FDIC. Learn more at Truist.com.

About Pollinate

Founded in 2017, Pollinate is a global fintech dedicated to ensuring that banks are at the heart of every Small and Medium-sized Business (SMB). Pollinate’s proprietary, digital experience platform enables banks to better integrate merchant acquiring with business banking for their SMB customers. This platform brings together a comprehensive suite of bank and third-party products for SMBs through a single, bank-owned solution. Pollinate’s platform is trusted by banks and their merchants around the world. The company’s investors include Mastercard, NatWest, NAB, CIBC, Fiserv, EFM Asset Management, and Insight Partners.

 

View original content:https://www.prnewswire.com/news-releases/truist-merchant-engage-powers-smb-growth-in-banks-latest-payments-suite-expansion-302499178.html

SOURCE Truist Financial Corporation

Transaction expected to facilitate enhanced focus on Xtant’s core businesses

Total consideration of approximately $19.2 million allows Xtant to
reduce outstanding debt and improve liquidity

BELGRADE, Mont.
, July 8, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the company has entered into agreements to sell certain Coflex^® and CoFix^® interlaminar stabilization implant assets and all OUS entities of Paradigm Spine GmbH, to Companion Spine, LLC, a French-American company fully dedicated to posterior dynamic spine stabilization and motion preservation systems for the treatment of spine and back pain. Companion Spine is a portfolio company of Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space.

The proceeds of the transaction total $19.2 million, consisting of $11 million in cash at closing and $8.2 million in short-term seller financing.  Xtant expects to use the proceeds to reduce long-term debt and provide additional cash liquidity. The transaction is expected to close in the third quarter of 2025.  As part of the transaction, Companion Spine expects to transition certain members of the Xtant U.S. and international commercial organizations, who will continue to support these products.      

Sean Browne, President and CEO of Xtant Medical, stated, “This transaction is a significant step for us as we focus on our core business – the development of higher-margin, best-in-class orthobiologics – while also strengthening our balance sheet and streamlining our operations.  At the same time, these franchises will be in great hands given the Viscogliosi Brothers’ proven track record of successful commercial execution in the neuro-musculoskeletal space. We believe they, along with Companion Spine, are the ideal partners to continue driving the growth of Coflex, CoFix, HPS, and related spinal fixation technologies.  This transaction places Paradigm Spine with a team of people who are well-equipped to complete the remaining clinical and regulatory work and take these fantastic technologies to the next level. We look forward to completing this transaction in a timely manner.”

Anthony G. Viscogliosi, Principal at Viscogliosi Brothers, LLC, and Co-founder, Executive Chairman and CEO of Companion Spine, added, “The addition of these spine implant solutions will significantly strengthen Companion Spine’s product solutions portfolio, reinforcing our commitment to innovation and excellence in spine care. We are confident this will position us to better serve the needs of pain management physicians, spine surgeons, and their patients on a global scale, strengthening specifically our presence in the U.S. This acquisition will position us as the largest posterior and cervical dynamic stabilization franchise business in the world.”

This transaction is subject to Companion Spine obtaining financing and other customary closing conditions.

Simultaneously with the execution of the definitive agreements, $2.5 million of the aggregate purchase price was paid to Xtant as a non-refundable cash deposit, except in the event Companion Spine terminates the Coflex/CoFix agreement due to certain breaches by Xtant under the agreement. Up to two additional $2.5 million cash deposits may be paid to Xtant by Companion Spine in the event it requires extra time to obtain financing. Assuming Companion receives its funding, it would pay Xtant an additional $8.5 million at or prior to closing, along with a further $8.2 million in the form of an unsecured promissory note to be issued by Companion Spine to Xtant. The promissory note will mature on December 31, 2025.

Xtant Medical will provide a further update on this transaction during its regularly scheduled second quarter results conference call in August.

About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

About Companion Spine
Founded in 2020 in New-York, United States, and Bordeaux, France, Companion Spine is a global company specialized in the treatment of spine degenerative conditions. Companion Spine’s comprehensive system of technologies and solutions target degenerative disc disease and lumbar spine stenosis, two of the most common indications for back and leg pain worldwide. Companion Spine proposes a portfolio of solutions that allows spine specialists to offer their patients earlier, effective, reversible and minimally invasive alternatives to more invasive procedures.

For more information, please visit: www.companion-spine.com

About Viscogliosi Brothers, LLC
Viscogliosi Brothers is a family-owned single New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of multiple businesses in the spine industry specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma, Woven Orthopedics Technologies and VB Spine, among others. For more information, visit https://www.vbllc.com/.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as “intends,” ”expects,” ”anticipates,” ”plans,” ”believes,” ”estimates,” “continue,” “future,” ”will,” “potential,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the anticipated sale of the Company’s Coflex and CoFix products and international business, the timing thereof, and net proceeds to be received by the Company and its use thereof. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the possibility that the sale of the Company’s Coflex and CoFix products and international business are not completed or, if completed, that the anticipated benefits of the transactions are not realized when expected or at all; the possibility that the transactions may be more expensive to complete than anticipated; diversion of management’s attention from ongoing business operations and opportunities; the occurrence of any event, change or other circumstances that could give rise to the right of the parties to terminate either or both transactions; exposure to potential litigation and adverse tax consequences; the Company’s future operating results and financial performance; the Company’s ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the SEC on May 12, 2025. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-announces-definitive-agreements-for-the-sale-of-its-coflex-and-cofix-spinal-implants-and-all-ous-businesses-to-companion-spine-302499312.html

SOURCE Xtant Medical Holdings, Inc.